Advertisement
Singapore markets close in 3 hours 9 minutes
  • Straits Times Index

    3,343.40
    +12.59 (+0.38%)
     
  • Nikkei

    38,626.26
    -77.25 (-0.20%)
     
  • Hang Seng

    18,357.41
    -119.39 (-0.65%)
     
  • FTSE 100

    8,285.34
    +38.39 (+0.47%)
     
  • Bitcoin USD

    71,432.12
    +581.12 (+0.82%)
     
  • CMC Crypto 200

    1,485.26
    -39.54 (-2.59%)
     
  • S&P 500

    5,352.96
    -1.07 (-0.02%)
     
  • Dow

    38,886.17
    +78.84 (+0.20%)
     
  • Nasdaq

    17,173.12
    -14.78 (-0.09%)
     
  • Gold

    2,399.30
    +8.40 (+0.35%)
     
  • Crude Oil

    75.73
    +0.18 (+0.24%)
     
  • 10-Yr Bond

    4.2810
    -4.2890 (-50.05%)
     
  • FTSE Bursa Malaysia

    1,617.62
    +2.89 (+0.18%)
     
  • Jakarta Composite Index

    6,935.26
    -39.64 (-0.57%)
     
  • PSE Index

    6,526.25
    +16.39 (+0.25%)
     

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

ADVERTISEMENT

Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-bank-of-america-securities-2024-health-care-conference-302140895.html

SOURCE Syndax Pharmaceuticals, Inc.